Results 141 to 150 of about 28,581 (233)

Stage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities. [PDF]

Biomolecules
Dong X, Wu X, You Z, Lu K, Cai H, Zhang B, Gong Y, Wang Q, Yuan Y, Tu H.   +9 more
europepmc   +1 more source

Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma. [PDF]

Cancer Res Commun
Meermeier EW, Missan DS, Pathangey LB, Stein CK, Reckard GA, Darvish SA, Ahmann GJ, Adamski J, Fonseca R, Gendler SJ, Gustafson MP, Bergsagel PL.   +11 more
europepmc   +1 more source

MUC1 Antibody [PDF]

, 2020
openaire   +1 more source

Interferome profiling in the blood links IFNα5-Mucin-1 axis to HIV-1 pathogenesis. [PDF]

J Virol
Guo K, Dillon SM, Meneses EC, Barrett BS, Norman A, Mickens KL, Morrison JH, Dittmer U, Sutter K, Poeschla EM, Kechris K, Wilson CC, Santiago ML.   +12 more
europepmc   +1 more source

Intrahepatic intraductal papillary neoplasm of the bile duct with low-grade dysplasia presenting as high biliary obstruction and hepatolithiasis: a case report. [PDF]

Front Med (Lausanne)
Long J, Xue J, Xie N, Zhang L, Zhou K.
europepmc   +1 more source

Identification of IL1RN, MUC1, and SERPINA1 as key NET-related biomarkers in ulcerative colitis-associated intestinal fibrosis via bioinformatics and experimental validation. [PDF]

BMC Gastroenterol
Chuai Q, Jiang X, Li K, Liu X, Guo J, Liu J.   +5 more
europepmc   +1 more source

Design, build and test of a targeted synthetic protein strategy. [PDF]

Front Bioeng Biotechnol
Yallapragada VVB, Shukla A, Devoy C, Tangney M.   +3 more
europepmc   +1 more source

Evolution of <i>MUC1</i> During Retrotransposon Expansion as a Potential Adaptation Exploited in Human Cancer. [PDF]

Int J Mol Sci
Haratake N, Takamori S, Shigeta K, Kufe D.   +3 more
europepmc   +1 more source

MUC1 Positive [PDF]

, 2020
openaire   +1 more source

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer. [PDF]

Oncoimmunology
Wang CX, Luxardi G, Mori H, Maverakis EM, Merleev AA, Marusina AI, Borowsky AD, Parikh M, Riess JW, Moshiri A, Bazhenova L, Gubens M, Koczywas M, Butner JD, Huang J, Kim SK, Vick LV, Sun Y, Canter RJ, Murphy WJ, Daly ME, Kelly K, Monjazeb AM.   +22 more
europepmc   +1 more source